SUMMARY: Recent pathologic and MR imaging studies have challenged the classic view of MS as a chronic inflammatory-demyelinating condition affecting solely the WM of the central nervous system. Indeed, an involvement of the GM has been shown to occur from the early stages of the disease, to progress with time, and to be only moderately correlated with the extent of WM injury. In this review, we summarize how advances in MR imaging technology and methods of analysis are contributing to ameliorating the detection of focal lesions and to quantifying the extent of "occult" pathology and atrophy, as well as to defining the topographic distribution of such changes in the GM of patients with MS. These advances, combined with the imaging of brain reorganization occurring after tissue injury, should ultimately result in an improved understanding and monitoring of MS clinical manifestations and evolution, either natural or modified by treatment.ABBREVIATIONS: Cereb ϭ cerebellum; Cho ϭ choline; CIS ϭ clinically isolated syndromes; DIR ϭ double inversion recovery; DTI ϭ diffusion tensor imaging; EDSS ϭ Expanded Disability Status Scale; FA ϭ fractional anisotropy; FLAIRϭ fluid-attenuated inversion recovery; fMRI ϭ functional MR imaging; GM ϭ gray matter; L ϭ left; MD ϭ mean diffusivity; MS ϭ multiple sclerosis; MT ϭ magnetization transfer; MTR ϭ magnetization transfer ratio; NAA ϭ N-acetylaspartate; NAWM ϭ normal-appearing white matter; PM ϭ premotor cortex; PPMS ϭ primary-progressive MS; R ϭ right; RRMS ϭ relapsing-remitting MS; RT ϭ relaxation time; SII ϭ secondary sensorimotor cortex; SMA ϭ supplementary motor area; SMC ϭ sensorimotor cortex; SPM ϭ statistical parametric mapping; SPMS ϭ secondary-progressive MS; Thal ϭ thalamus; WM ϭ white matter P athologic and MR imaging studies are challenging the view of MS as a chronic inflammatory-demyelinating condition affecting solely the WM of the central nervous system. Indeed, there is a growing body of evidence showing that a significant portion of MS-related damage affects virtually all the GM structures. Pathologically, cortical lesions have been distinguished in mixed WM-GM lesions (type I) and purely intracortical lesions (types II, III, and IV).1 The latter may represent more than two-thirds of macroscopic cortical pathology in the disease, 1 and the extent of cortical demyelination can exceed that occurring in the WM.1 Demyelination is seen not only in the neocortex (especially in the cingulate cortex) 1,2 but also in the GM of the thalamus, basal ganglia, hypothalamus, hippocampus, cerebellum, and spinal cord. Compared with WM lesions, GM lesions are characterized by a much milder lymphocytic infiltration, less microglial activation, and fewer perivascular cuffs.3 GM lesions also lack complement deposition and have only a modest increase in bloodbrain barrier permeability.2 In MS, GM pathology also includes neuronal injury, with neuritic swelling as well as dendritic and axonal transections.2 In addition to focal lesions, wallerian and trans-synaptic degeneration of fi...